Apixaban versus warfarin in patients with atrial fibrillation

Cited by (1,013)

Items 201–300 of 1,013

1. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR
   Nicolas M. Van Mieghem, Martin Unverdorben, Christian Hengstenberg, Helge Möllmann, Roxana Mehran, Diego López-Otero, Luis Nombela-Franco y, Raul Moreno, Peter Nordbeck, Holger Thiele et al. · 2021 · New England Journal of Medicine
2. Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes
   Stacy B. Westerman, NANETTE KASS WENGER · 2018 · Current Cardiology Reviews
3. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
   Laurent Macle, John A. Cairns, Kori Leblanc, Teresa S.M. Tsang, Allan Cameron Skanes, Jafna L. Cox, Jeff S. Healey, Alan Bell, Louise Pilote, Jason G. Andrade et al. · 2016 · Canadian Journal of Cardiology
4. 2020 ACC/AHA guideline for the management of patients with valvular heart disease
   Otto, Catherine M., Nishimura, Rick A., Bonow, Robert O., Carabello, Blase A., Erwin, John P., Gentile, Federico, Jneid, Hani, Krieger, Eric V., Mack, Michael, McLeod, Christopher et al. · 2021 · The Journal of Thoracic and Cardiovascular Surgery
5. Left Ventricular Thrombus After Acute Myocardial Infarction
   Cian P. McCarthy, Muthiah Vaduganathan, Killian J. McCarthy, James L. Januzzi, Deepak L. Bhatt, John William McEvoy · 2018 · JAMA Cardiology
6. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
   Vijay V. Upreti, Jessie J.J. Wang, Yu Chen Barrett, Wonkyung Byon, Rebecca A. Boyd, Janice M. Pursley, Frank P. LaCreta, Charles E. Frost · 2013 · British Journal of Clinical Pharmacology
7. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
   Gregory Y.H. Lip, J.P. Collet, Michael Haude, Robert Byrne, Eugene H. Chung, Laurent Fauchier, Sigrun Halvorsen, Dennis H. Lau, Néstor López-Cabanillas, Maddalena Lettino et al. · 2018 · EP Europace
8. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
   Karen L. Furie, Larry B. Goldstein, Gregory W. Albers, Pooja Khatri, Ron R. Neyens, Mintu P. Turakhia, Tanya N. Turan, Kathryn Wood · 2012 · Stroke
9. Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
   Matthew William Sherwood, James Demetrios Douketis, Manesh R. Patel, Jonathan Paul Piccini, Anne S. Hellkamp, Yuliya V. Lokhnygina, Alex C. Spyropoulos, Graeme J. Hankey, Daniel E. Singer, Christopher C. Nessel et al. · 2014 · Circulation
10. New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials
    Partha Sardar, Saurav Chatterjee, Shobhana Chaudhari, Gregory Y.H. Lip · 2014 · Journal of the American Geriatrics Society
11. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
    Allison V. Keshishian, Shital Kamble, Xianying Pan, Jack Mardekian, Ruslan V. Horblyuk, Melissa Hamilton, Gregory Y.H. Lip · 2016 · Thrombosis and Haemostasis
12. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
    Raffaele De Caterina, Steen Husted, Lars C. Wallentin, Raffaele De Caterina, Steen Husted, Lars C. Wallentin, Felicita Andreotti, Harald Arnesen, F Bachmann, Colin Baigent et al. · 2012 · Journal of the American College of Cardiology
13. Causes of Death in Anticoagulated Patients With Atrial Fibrillation
    Antonio Gómez‐Outes, Julián Lagunar-Ruíz, Ana‐Isabel Terleira‐Fernández, Gonzalo Calvo, Maria Luisa Suárez-Gea, Emilio Vargas · 2016 · Journal of the American College of Cardiology
14. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013):– Digest Version –
    JCSJointWorkingGroup · 2014 · Circulation
15. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation
    Aya Fukuma Ozaki, A. Choi, Quan T. Le, Dennis T. Ko, Janet K. Han, Sandy S. Park, Cynthia Anne Jackevicius · 2020 · Circulation Cardiovascular Quality and Outcomes
16. Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Amanda R. Harrington, Edward P. Armstrong, Paul E. Nolan, Daniel C. Malone · 2013 · Stroke
17. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
    Chao, Tze-Fan, Liu, Chia-Jen, Wang, Kang-Ling, Lin, Yenn-Jiang, Chang, Shih-Lin, Lo, Li-Wei, Hu, Yu-Feng, Tuan, Ta-Chuan, Chen, Tzeng-Ji, Lip, Gregory Y.H. et al. · 2015 · Journal of the American College of Cardiology
18. Hypertension and Atrial Fibrillation
    Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi · 2018 · Circulation Research
19. Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association
    Amish N. Raval, Joaquin E. Cigarroa, Mina K. Chung, Larry J. Díaz‐Sandoval, Deborah Diercks, Jonathan Paul Piccini, Hee Soo Jung, Jeffrey B. Washam, Babu Guai Welch, Allyson R. Zazulia et al. · 2017 · Circulation
20. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation
    Xiaoxi Yao, Navdeep Tangri, Bernard John Gersh, Lindsey R. Sangaralingham, Nilay D. Shah, Karl A. Nath, Peter A. Noseworthy · 2017 · Journal of the American College of Cardiology
21. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials
    William F. McIntyre, Alexander Philipp Benz, Nina Becher, Jeff S. Healey, Christopher Bull Granger, Léna Rivard, A. John Camm, Andreas Goette, Antonia Zapf, Marco Alings et al. · 2023 · Circulation
22. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary
    Jan Steffel, Peter B. Verhamme, Tatjana Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldán et al. · 2018 · EP Europace
23. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi
    Austin A. Robinson, Cory Ross Trankle, Grayson C. Eubanks, Christopher L. Schumann, Paul Thompson, Ryan L. Wallace, Shouri Gottiparthi, Benjamin K. Ruth, Christopher M. Kramer, Michael Salerno et al. · 2020 · JAMA Cardiology
24. Atrial Fibrillation
    PETER J. ZIMETBAUM · 2017 · Annals of Internal Medicine
25. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism
    Manuj Sharma, Victoria R. Cornelius, Jignesh Prakash Patel, Graham Davies, Mariam Molokhia · 2015 · Circulation
26. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease
    Paul Khairy, George F. Van Hare, Seshadri Balaji, Charles I. Berul, Frank Cecchin, Mitchell I. Cohen, Curt J. Daniels, Barbara J. Deal, Joseph A. Dearani, Natasja M. S. de Groot et al. · 2014 · Canadian Journal of Cardiology
27. Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
    Daniel E. Singer, Anne S. Hellkamp, Jonathan Paul Piccini, Kenneth W. Mahaffey, Yuliya V. Lokhnygina, Guohua Pan, Jonathan L. Halperin, Richard Clinton Becker, GÜNTER E. BREITHARDT, Graeme J. Hankey et al. · 2013 · Journal of the American Heart Association
28. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
    Álvaro Avezum, Renato D. Lópes, Phillip J. Schulte, Fernando Tomas Lanas, Bernard John Gersh, Michael Hanna, Prem Pais, Çetin Erol, Rafael Díaz, Maria Cecilia Bahit et al. · 2015 · Circulation
29. Sex Differences in Stroke Risk Among Older Patients With Recently Diagnosed Atrial Fibrillation
    Cynthia A. Jackevicius · 2012 · JAMA
30. Trends in the prescription of novel oral anticoagulants in UK primary care
    Simone Y. Loo, Sophie Dell’Aniello, Laëtitia Huiart, Christel Renoux · 2017 · British Journal of Clinical Pharmacology
31. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
    Felicita Andreotti, Bianca Rocca, Steen Husted, Ramzi Ajjan, Jurriën M. ten Berg, Marco Cattaneo, Jean‐Philippe Collet, Raffaele De Caterina, Keith A.A. Fox, Sigrun Halvorsen et al. · 2015 · European Heart Journal
32. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation
    David Julian Seiffge, David John Werring, Maurizio Paciaroni, Jesse Dawson, Steven J. Warach, Truman John Milling, Stefan T. Engelter, Urs Fischer, Bo G Norrving · 2018 · The Lancet Neurology
33. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial
    Sean D. Pokorney, Glenn Matthew Chertow, Hussein R. Al‐Khalidi, Dianne S. Gallup, Patricia Dignacco, Kurt Mussina, Nisha Bansal, Crystal Ann Gadegbeku, David A. Garcia, Samira J. Merali et al. · 2022 · Circulation
34. Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation
    Greg Flaker, Renato D. Lópes, Sana M. Al‐Khatib, Antonio G. Hermosillo, Stefan Hans Hohnloser, Brian Tinga, Jun Zhu, Puneet Mohan, David A. Garcia, Jozef Bartúnek et al. · 2013 · Journal of the American College of Cardiology
35. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
    Paulus F. Kirchhof, Karl Georg Hæusler, Benjamin Blank, Joseph Paul de Bono, David J. Callans, Arif Elvan, Thomas Fetsch, Isabelle C. Van Gelder, Philip J. Gentlesk, Massimo Grimaldi et al. · 2018 · European Heart Journal
36. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation
    Peter A. Noseworthy, Xiaoxi Yao, Neena S. Abraham, Lindsey R. Sangaralingham, Robert D. McBane, Nilay D. Shah · 2016 · CHEST Journal
37. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
    Dominick Joseph Angiolillo, Shaun G. Goodman, Deepak L. Bhatt, John W. Eikelboom, Matthew J. Price, David J. Moliterno, Christopher Paul Cannon, Jean‐François Tanguay, Christopher Bull Granger, Laura Mauri et al. · 2018 · Circulation
38. Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry
    Masaharu Akao, Yeong‐Hwa Chun, Hiromichi Wada, Masahiro Esato, Tetsuo Hashimoto, Mitsuru Abe, Koji Hasegawa, Hikari Tsuji, Keizo Furuke · 2013 · Journal of Cardiology
39. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
    Roopinder Kaur Sandhu, Justin Adrian Ezekowitz, Ulrika Andersson, John Hunter Alexander, Christopher Bull Granger, Sigrun Halvorsen, Michael Hanna, Ziad Hijazi, Petr Janský, Renato D. Lópes et al. · 2016 · European Heart Journal
40. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
    pre-diabetes Task Force on diabetes · 2014 · Diabetes and Vascular Disease Research
41. Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation
    Kang-Ling Wang, Gregory Y.H. Lip, Shing‐Jong Lin, Chern‐En Chiang · 2015 · Stroke
42. Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality
    Taku Inohara, Ying Xian, Li Liang, Roland Matsouaka, Jeffrey L. Saver, Eric Edward Smith, Lee H. Schwamm, Mathew J. Reeves, Adrian F. Hernandez, Deepak L. Bhatt et al. · 2018 · JAMA
43. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
    Jason G. Andrade, Atul Verma, L. Brent Mitchell, Ratika Parkash, Kori Leblanc, Clare L. Atzema, Jeff S. Healey, Alan Bell, John A. Cairns, Stuart J. Connolly et al. · 2018 · Canadian Journal of Cardiology
44. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management
    Pierre R. Tibi, Robert Scott McClure, Jiapeng Huang, Robert A. Baker, David C Fitzgerald, C. David Mazer, Marc E. Stone, Danny Chu, Alfred H. Stammers, Tim Dickinson et al. · 2021 · The Annals of Thoracic Surgery
45. N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation
    Hijazi, Ziad, Wallentin, Lars, Siegbahn, Agneta, Andersson, Ulrika, Christersson, Christina, Ezekowitz, Justin, Gersh, Bernard J., Hanna, Michael, Hohnloser, Stefan, Horowitz, John et al. · 2013 · Journal of the American College of Cardiology
46. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure
    Jeff S. Healey, Martina Brueckmann, John W. Eikelboom, Michael D. Ezekowitz, Mandy Fraessdorf, Herbert Noack, Jonas Oldgren, Paul A. Reilly, Alex C. Spyropoulos, Lars C. Wallentin et al. · 2014 · Thrombosis and Haemostasis
47. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017
    Junya Zhu, G. Caleb Alexander, Saman Nazarian, Jodi B Segal, Albert W. Wu · 2018 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
48. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review
    Borre, Ethan, Goode, Adam, Raitz, Giselle, Shah, Bimal, Lowenstern, Angela, Chatterjee, Ranee, Sharan, Lauren, Allen LaPointe, Nancy, Yapa, Roshini, Davis, J. et al. · 2018 · Thrombosis and Haemostasis
49. Guideline on the management of bleeding in patients on antithrombotic agents
    Mike Makris, Joost J. van Veen, Robert Campbell Tait, Andrew David Mumford, Michael Laffan · 2012 · British Journal of Haematology
50. Untitled work
    Goodman · 2014 · 10.1016/j.jacc.2013.11.013
51. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
    Thomas A. Mavrakanas, Caroline Flora Samer, Sharon J. Nessim, Gershon Frisch, Mark L. Lipman · 2017 · Journal of the American Society of Nephrology
52. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
    Paulus F. Kirchhof, Benjamin F. Blank, Melanie Calvert, A. John Camm, GREGORY I. CHLOUVERAKIS, Hans‐Christoph Diener, Andreas Goette, Andrea Huening, Gregory Y.H. Lip, EMMANUEL N. SIMANTIRAKIS et al. · 2017 · American Heart Journal
53. Pros and cons of new oral anticoagulants
    Kenneth Alan Bauer · 2013 · Hematology
54. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter
    M. S. Arakelyan, Leo A. Bockeria, Elena Vasilieva, Golitsyn Sp, Elena Zelikovna Golukhova, M. V. Gorev, Karapet V. Davtyan, Oksana M. Drapkina, Кропачева Екатерина Станиславовна, Е. А. Kuchinskaya et al. · 2021 · Russian Journal of Cardiology
55. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
    Kevin E. Chan, Robert Patrick Giugliano, Manesh R. Patel, Stuart Abramson, Meg Jardine, Sophia J. Zhao, Vlado Perkovic, Franklin W. Maddux, Jonathan Paul Piccini · 2016 · Journal of the American College of Cardiology
56. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation
    Ying Xian, Emily Claire O'Brien, Li Liang, Haolin Xu, Lee H. Schwamm, Gregg C. Fonarow, Deepak L. Bhatt, Eric Edward Smith, DaiWai M. Olson, Lesley Maisch et al. · 2017 · JAMA
57. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines
    Andrew Veitch, Geoffroy Vanbiervliet, Anthony Gershlick, Christian Boustière, Trevor P Baglin, Lesley‐Ann Smith, Franco Radaelli, Evelyn Knight, Ian Mark Gralnek, Cesare Hassan et al. · 2016 · Endoscopy
58. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
    Gregory Y.H. Lip, António Coca, Thomas Kahan, Giuseppe Boriani, Antonis S. Manolis, Michael Hecht Olsen, Ali̇ Oto, Tatjana Potpara, Jan Steffel, Francisco R. Marín et al. · 2017 · EP Europace
59. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology
    Massimo Francesco Piepoli, Ana Abreu, Christian Albus, Marco Ambrosetti, Carlos Brotons, Alberico Luigi Catapano, Ugo Corrà, Bernard Cosyns, Christi Deaton, Ian M Graham et al. · 2019 · European Journal of Preventive Cardiology
60. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
    Stuart J. Connolly, Lars C. Wallentin, Michael D. Ezekowitz, John W. Eikelboom, Jonas Oldgren, Paul A. Reilly, Martina Brueckmann, Janice M. Pogue, Marco Alings, John V. Amerena et al. · 2013 · Circulation
61. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
    Benjamin Adam Steinberg, Haiyan Gao, Peter J. Shrader, Karen Pieper, Laine Elliott Thomas, A. John Camm, Michael D. Ezekowitz, Gregg C. Fonarow, Bernard John Gersh, Samuel Zachary Goldhaber et al. · 2017 · American Heart Journal
62. Digoxin and Mortality in Patients With Atrial Fibrillation
    Renato D. Lópes, Roberto Rordorf, Gaetano Maria De Ferrari, Sergio Leonardi, Laine Elliott Thomas, DANIEL M. WOJDYLA, Peter Ridefelt, John H. Lawrence, Raffaele De Caterina, Dragoş Vinereanu et al. · 2018 · Journal of the American College of Cardiology
63. Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation
    Lars C. Wallentin, Renato D. Lópes, Michael Hanna, Laine Elliott Thomas, Anne S. Hellkamp, Sunil Nepal, Elaine M. Hylek, Sana M. Al‐Khatib, John Hunter Alexander, Marco Alings et al. · 2013 · Circulation
64. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies
    Apostolos Tzikas, David R. Holmes, Sameer A. Gafoor, Carlos Eduardo Ruiz, Carina Blomström‐Lundqvist, Hans‐Christoph Diener, Riccardo Cappato, Saibal Kar, Randal J. Lee, Robert A. Byrne et al. · 2016 · EP Europace
65. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation
    George Ntaios, Vasileios Papavasileiou, Konstantinos P. Makaritsis, Konstantinos N. Vemmos, Patrik Michel, Gregory Y.H. Lip · 2017 · Stroke
66. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial
    Jean‐Philippe Collet, Eric Van Belle, Hölger Thiele, Sérgio Luis Berti, Thibault Lhermusier, Thibault Manigold, Franz‐Josef Neumann, Martine Gilard, David Attias, Farzin Beygui et al. · 2022 · European Heart Journal
67. Comorbidity of atrial fibrillation and heart failure
    Liang‐Han Ling, Peter M. Kistler, Jonathan M. Kalman, RICHARD JOHN SCHILLING, Ross Jacob Hunter · 2015 · Nature Reviews Cardiology
68. Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation
    Matthew J. Price, Douglas N Gibson, Steven Joseph Yakubov, Jason C. Schultz, Luigi Di Biase, Andrea Natale, J. David Burkhardt, Ashish Pershad, Timothy Byrne, Brett Gidney et al. · 2014 · Journal of the American College of Cardiology
69. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation
    Yukiko Matsumura‐Nakano, Satoshi Shizuta, Akihiro Komasa, Takeshi Morimoto, Hisaki Masuda, Hiroki Shiomi, Koji Goto, Kentaro Nakai, Hisashi Ogawa, Atsushi Kobori et al. · 2019 · Circulation
70. 2024 Clinical practice guidelines for Chronic heart failure
    Albert S. Galyavich, Sergey N. Tereshchenko, T. M. Uskach, Fail T. Ageev, D. M. Aronov, G. P. Arutyunov, Yu. L. Begrambekova, Yu. N. Belenkov, Sergey Anatol'evich Boytsov, Marina Gennad'evna Bubnova et al. · 2024 · Russian Journal of Cardiology
71. Patent foramen ovale
    Shunichi Homma, Steven Russell Messe, Tatjana Rundek, Yee‐Ping Sun, Jennifer Franke, Karina W. Davidson, Horst Sievert, Ralph L. Sacco, Marco R. Di Tullio · 2016 · Nature Reviews Disease Primers
72. Atrial Fibrillation
    Darae Ko, Mina K. Chung, Peter T. Evans, Emelia J. Benjamin, Robert H. Helm · 2024 · JAMA
73. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
    Renato D. Lópes, Sana M. Al‐Khatib, Lars C. Wallentin, Hongqiu Yang, Jack Ansell, Maria Cecilia Bahit, Raffaele De Caterina, Paul Dorian, J. Donald Easton, Çetin Erol et al. · 2012 · The Lancet
74. Rates of hemorrhage during warfarin therapy for atrial fibrillation
    Tara Gomes, Muhammad Mamdani, Anne Marie Holbrook, John Michael Paterson, Chelsea Hellings, David Nelson Juurlink · 2012 · Canadian Medical Association Journal
75. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
    Benjamin Adam Steinberg, Peter J. Shrader, Karen S. Pieper, Laine Elliott Thomas, Larry A. Allen, Jack Ansell, Paul S. Chan, Michael D. Ezekowitz, Gregg C. Fonarow, James V. Freeman et al. · 2018 · Journal of the American Heart Association
76. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
    Pancholy, Samir B., Sharma, Parikshit S., Pancholy, Dipti S., Patel, Tejas M., Callans, David J., Marchlinski, Francis E. · 2014 · The American Journal of Cardiology
77. Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications
    Nihar R. Desai, Alexis A. Krumme, Sebastian Schneeweiß, William H. Shrank, Gregory E. Brill, Edmund J. Pezalla, Claire M. Spettell, Troyen A. Brennan, Olga S. Matlin, Jerry Avorn et al. · 2014 · The American Journal of Medicine
78. New Oral Anticoagulants and the Cancer Patient
    Nicholas James Short, Jean M. Connors · 2013 · The Oncologist
79. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
    Mohammed Alquwaizani, Leo Francis Buckley, Christopher Adams, John R. Fanikos · 2013 · Current Emergency and Hospital Medicine Reports
80. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
    Stefan Agewall, Marco Cattaneo, J.‐P. Collet, Felicita Andreotti, Gregory Y.H. Lip, Freek W.A. Verheugt, Kurt Huber, Erik Lerkevang Grove, João Morais, Steen Husted et al. · 2013 · European Heart Journal
81. Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban
    Inna Y. Gong, Richard B. Kim · 2013 · Canadian Journal of Cardiology
82. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
    Sean D. Pokorney, Jonathan Paul Piccini, Susanna R. Stevens, Manesh R. Patel, Karen S. Pieper, Jonathan L. Halperin, GÜNTER E. BREITHARDT, Daniel E. Singer, Graeme J. Hankey, Werner Hacke et al. · 2016 · Journal of the American Heart Association
83. Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020
    Ann Marie Návar, Ahmed A. Kolkailah, Robert A. Overton, Nishant P. Shah, Justin F. Rousseau, Greg C. Flaker, Michael Patrick Pignone, Eric David Peterson · 2022 · Journal of the American Heart Association
84. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
    Oldgren, J., Wallentin, L., Alexander, J. H., James, S., Jonelid, B., Steg, G., Sundstrom, J. · 2013 · European Heart Journal
85. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms
    Francesco Violi, Elsayed Z. Soliman, Pasquale Pignatelli, Daniele Pastori · 2016 · Journal of the American Heart Association
86. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Circulation Journal
87. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis
    Jonathan A C Sterne, Pritesh N. Bodalia, Peter A. Bryden, Philippa A. Davies, José A López-López, George N. Okoli, Howard H. Z. Thom, Deborah M Caldwell, Sofia Dias, Diane Eaton et al. · 2017 · Health Technology Assessment
88. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension
    Manolis, Athanasios J., Rosei, Enrico Agabiti, Coca, Antonio, Cifkova, Renata, Erdine, Serap E., Kjeldsen, Sverre, Lip, Gregory Y.H., Narkiewicz, Krzysztof, Parati, Gianfranco, Redon, Josep et al. · 2012 · Journal of Hypertension
89. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
    Breithardt, Günter, Baumgartner, Helmut, Berkowitz, Scott D., Hellkamp, Anne S., Piccini, Jonathan P., Stevens, Susanna R., Lokhnygina, Yuliya, Patel, Manesh R., Halperin, Jonathan L., Singer, Daniel E. et al. · 2014 · European Heart Journal
90. Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques
    Pierre Amarenco, Stephen M. Davis, Elizabeth F. Jones, Ariel A. Cohen, Wolf‐Dieter Heiss, Markku Kaste, Cédric Laouenan, Dennis Young, Malcolm Robert Macleod, Geoffrey Alan Donnan et al. · 2014 · Stroke
91. The State of the Art
    Daniel P. Morin, Michael L. Bernard, Christopher A. Madias, Paul A. Rogers, Sudarone Thihalolipavan, N.A. Mark Estes · 2016 · Mayo Clinic Proceedings
92. New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists
    Francesco Scaglione · 2013 · Clinical Pharmacokinetics
93. Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism
    Soheir S. Adam, Jennifer R McDuffie, Thomas L. Ortel, John W Williams · 2012 · Annals of Internal Medicine
94. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial
    Sana M. Al‐Khatib, Laine Elliott Thomas, Lars C. Wallentin, Renato D. Lópes, Bernard John Gersh, David A. Garcia, Justin Adrian Ezekowitz, Marco Alings, Hongqui Yang, John Hunter Alexander et al. · 2013 · European Heart Journal
95. Rate control in atrial fibrillation
    Isabelle C. Van Gelder, Michiel Rienstra, Harry J.G.M. Crijns, Brian Olshansky · 2016 · The Lancet
96. Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies
    Jay Desai, Jennifer M. Kolb, Jeffrey Ian Weitz, James Aisenberg · 2013 · Thrombosis and Haemostasis
97. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
    Chern‐En Chiang, Ken Okumura, Shu Zhang, Tze‐Fan Chao, Chung‐Wah Siu, Toon Wei Lim, Anil Saxena, Yoshihide Takahashi, Wee Siong Teo · 2017 · Journal of Arrhythmia
98. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials
    Chatree Chai‐Adisaksopha, Christopher Hillis, Tetsuya Isayama, Wendy Lim, Alfonso Iorio, Mark Andrew Crowther · 2015 · Journal of Thrombosis and Haemostasis
99. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management
    Ka Shing Cheung, Wai K. Leung · 2017 · World Journal of Gastroenterology
100. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
     Jessica L. Mega, Joseph R. Walker, Christian Thomas Ruff, Alexander G. Vandell, Francesco Nordio, Naveen Deenadayalu, Sabina A. Murphy, James Lee, Michele F. Mercuri, Robert Patrick Giugliano et al. · 2015 · The Lancet